Open Access
Open access

Philosophical Magazine Letters

Taylor & Francis
Taylor & Francis
ISSN: 09500839, 13623036

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q3
WOS
Q4
Impact factor
1.2
SJR
0.344
CiteScore
2.6
Categories
Condensed Matter Physics
Areas
Physics and Astronomy
Years of issue
1981, 1987-2025
journal names
Philosophical Magazine Letters
PHIL MAG LETT
Publications
3 294
Citations
54 390
h-index
79
Top-3 organizations
Tohoku University
Tohoku University (50 publications)
University of Cambridge
University of Cambridge (41 publications)
Top-3 countries
China (451 publications)
USA (435 publications)
Japan (325 publications)

Most cited in 5 years

Found 
from chars
Publications found: 900
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E
Lozupone M., Dibello V., Daniele A., Panza F.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder
Carnero Contentti E., Correale J.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging treatments for sarcoma: from 2024 onward
Gómez-Puerto D., Cicala C.M., Valverde C., Serrano C.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging biological treatments for asthma
Pastore D., Lupia C., D’Amato M., Bruni A., Garofalo E., Longhini F., Gallelli L., Vatrella A., Pelaia G., Pelaia C.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Mitapivat: a step forward across different hemolytic diseases
Hodroj M.H., Klim J., Charbel N., Taher A.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
FcRn inhibitors in the context of myasthenia gravis
Menon D., Bhandari V.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?
Harvey P.D.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma
Mok K., Chen O., Yau J., Chan L.L., Chan S.L.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Seltorexant for major depressive disorder
Valentino K., Teopiz K.M., Wong S., Zhang M.C., Le G.H., Choi H., Ballum H., Dri C., Cheung W., McIntyre R.S.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Exploring emerging JAK inhibitors in the treatment of aicardi-goutières syndrome
Politano D., Tonduti D., Battini R., Fazzi E., Orcesi S.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis
Patel H.A., Tran L., Karagenova R., Feldman S.R.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?
Hansford J.R., Manoharan N., Bouche G., Ramaswamy V., Jabado N., Bouffet E.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results
Stella L., Hollande C., Merabet Y.B., Fakhouri H., Leclerc V., Ponziani F.R., Bouattour M.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion
Pan L., Nagib L., Ganguly S., Moorthy A., Tahir H.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 1
Current and emerging drug treatment strategies to tackle sickle cell anemia
Persaud Y., Leonard A., Rai P.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0

Top-100

Citing journals

500
1000
1500
2000
2500
Show all (70 more)
500
1000
1500
2000
2500

Citing publishers

5000
10000
15000
20000
25000
Show all (70 more)
5000
10000
15000
20000
25000

Publishing organizations

10
20
30
40
50
60
Show all (70 more)
10
20
30
40
50
60

Publishing organizations in 5 years

1
2
3
4
5
6
7
8
Show all (70 more)
1
2
3
4
5
6
7
8

Publishing countries

50
100
150
200
250
300
350
400
450
500
China, 451, 13.69%
USA, 435, 13.21%
Japan, 325, 9.87%
United Kingdom, 195, 5.92%
India, 189, 5.74%
France, 180, 5.46%
Germany, 157, 4.77%
Australia, 69, 2.09%
Russia, 54, 1.64%
Republic of Korea, 42, 1.28%
Austria, 38, 1.15%
Canada, 36, 1.09%
Italy, 34, 1.03%
Switzerland, 26, 0.79%
Turkey, 25, 0.76%
Spain, 24, 0.73%
Brazil, 19, 0.58%
Ukraine, 16, 0.49%
Ireland, 16, 0.49%
Czech Republic, 16, 0.49%
Belgium, 15, 0.46%
Portugal, 14, 0.43%
Netherlands, 14, 0.43%
Sweden, 14, 0.43%
Hungary, 13, 0.39%
Poland, 13, 0.39%
Mexico, 11, 0.33%
Saudi Arabia, 11, 0.33%
Norway, 9, 0.27%
Pakistan, 9, 0.27%
Algeria, 8, 0.24%
Denmark, 8, 0.24%
Tunisia, 8, 0.24%
Egypt, 7, 0.21%
Bulgaria, 6, 0.18%
Israel, 6, 0.18%
Singapore, 6, 0.18%
USSR, 6, 0.18%
Argentina, 5, 0.15%
Iran, 5, 0.15%
Morocco, 5, 0.15%
Romania, 5, 0.15%
Greece, 3, 0.09%
Cuba, 3, 0.09%
Timor-Leste, 2, 0.06%
Colombia, 2, 0.06%
Oman, 2, 0.06%
Slovakia, 2, 0.06%
Finland, 2, 0.06%
Chile, 2, 0.06%
Yugoslavia, 2, 0.06%
Kazakhstan, 1, 0.03%
Estonia, 1, 0.03%
Azerbaijan, 1, 0.03%
Botswana, 1, 0.03%
Brunei, 1, 0.03%
Venezuela, 1, 0.03%
Vietnam, 1, 0.03%
Indonesia, 1, 0.03%
Lebanon, 1, 0.03%
Luxembourg, 1, 0.03%
Malaysia, 1, 0.03%
New Zealand, 1, 0.03%
Slovenia, 1, 0.03%
Sudan, 1, 0.03%
Croatia, 1, 0.03%
South Africa, 1, 0.03%
Show all (37 more)
50
100
150
200
250
300
350
400
450
500

Publishing countries in 5 years

10
20
30
40
50
60
70
80
China, 72, 40.91%
India, 29, 16.48%
USA, 20, 11.36%
Japan, 16, 9.09%
France, 7, 3.98%
Republic of Korea, 5, 2.84%
Germany, 4, 2.27%
United Kingdom, 4, 2.27%
Turkey, 4, 2.27%
Australia, 3, 1.7%
Saudi Arabia, 3, 1.7%
Tunisia, 3, 1.7%
Russia, 2, 1.14%
Canada, 2, 1.14%
Morocco, 2, 1.14%
Pakistan, 2, 1.14%
Czech Republic, 2, 1.14%
Sweden, 2, 1.14%
Austria, 1, 0.57%
Algeria, 1, 0.57%
Brazil, 1, 0.57%
Vietnam, 1, 0.57%
Denmark, 1, 0.57%
Spain, 1, 0.57%
Italy, 1, 0.57%
Mexico, 1, 0.57%
Netherlands, 1, 0.57%
Norway, 1, 0.57%
Oman, 1, 0.57%
Chile, 1, 0.57%
Switzerland, 1, 0.57%
Show all (1 more)
10
20
30
40
50
60
70
80